文献速递糖尿病肥胖与代谢综合征

单分子GLP-1/APJ受体共激动剂改善高脂饮食小鼠代谢与血脂异常并正常化肝脏甘油三酯和转氨酶升高

Unimolecular GLP-1/APJ receptor co-agonism improves metabolism and dyslipidaemia as well as normalising hepatic triglyceride and aminotransferase elevation in high-fat-fed mice.
PubMed 文献 · Diabetologia · 2026-09-18

本研究在高脂饮食小鼠中每日给药28天,评估单分子GLP-1/APJ受体共激动剂ELA及其长效酰化版本ELA-Lys12(γGluPal)的代谢效应,以利拉鲁肽为阳性对照。结果显示两者降低摄食、血糖和HbA1c,ELA-Lys12(γGluPal)改善糖耐量和丙酮酸耐量,降低循环甘油三酯和LDL胆固醇,并完全正常化肝脏甘油三酯和转氨酶水平。

要点

  • ELA-Lys12(γGluPal)降低高脂饮食小鼠摄食、血糖和HbA1c,改善糖耐量和丙酮酸耐量。
  • GLP-1/apelin杂合体降低循环甘油三酯和LDL胆固醇,并完全正常化肝脏甘油三酯和转氨酶。
  • 与利拉鲁肽不同,GLP-1/apelin杂合体不影响自主活动,且恢复代谢灵活性。

核心结论

  • 长期给予ELA尤其是ELA-Lys12(γGluPal)在高脂饮食小鼠中产生显著代谢改善,与利拉鲁肽的最明显差异在循环血脂和肝脏生物标志物。

研究设计与样本

  • 高脂饮食小鼠每日一次给药28天,比较ELA、ELA-Lys12(γGluPal)与生理盐水及利拉鲁肽阳性对照。
  • 检测摄食、体重、葡萄糖/丙酮酸/胰岛素耐量、循环血脂、肝转氨酶和甘油三酯、间接测热及胰腺形态。

主要发现

  • ELA及尤其ELA-Lys12(γGluPal)相对生理盐水对照降低摄食、循环葡萄糖和HbA1c浓度。
  • ELA-Lys12(γGluPal)在葡萄糖和丙酮酸耐量试验中大幅降低血糖,且 largely 不依赖循环胰岛素变化。
  • 循环甘油三酯和LDL胆固醇降低,所有GLP-1/apelin杂合体治疗组肝脏甘油三酯和转氨酶完全正常化。
  • 间接测热显示ELA-Lys12(γGluPal)恢复代谢灵活性,尽管能量消耗降低。
  • GLP-1/apelin杂合体不影响自主活动,而利拉鲁肽显著降低体力活动;所有治疗均增强β细胞增殖频率并抑制凋亡率。

临床怎么用

  • GLP-1/APJ双激活可能作为肥胖和糖尿病的下一代治疗选项,尤其利于改善血脂和肝脏指标。

局限性

  • 研究为高脂饮食小鼠模型,结果尚未在人体中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of this study was to determine the applicability of dual activation of glucagon-like peptide-1 (GLP-1) and apelin (APJ) receptors as a next-generation therapeutic option for obesity and diabetes. METHODS: A fully characterised unimolecular dual GLP-1/APJ receptor agonist, namely exendin-linker-apelin (ELA), as well as its acylated long-acting equivalent, ELA-Lys12(γGluPal), were administered once daily to high-fat-fed (HFF) mice for 28 days, with liraglutide used as a positive control. Effects on appetite and body weight, as well as glucose, pyruvate and insulin tolerance, circulating lipids, liver transaminases and triglyceride content, indirect calorimetry measurements and pancreatic morphology were then examined. RESULTS: ELA, and particularly ELA-Lys12(γGluPal), reduced food intake, circulating glucose and HbA1c concentrations relative to saline-treated HFF control mice. ELA-Lys12(γGluPal) substantially reduced blood glucose concentrations during glucose and pyruvate tolerance tests. These positive effects were largely independent of alterations in circulating insulin. However, circulating triglyceride and LDL-cholesterol concentrations were lowered, accompanied by complete normalisation of hepatic triglyceride and aminotransferase levels in all GLP-1/apelin hybrid-treated HFF mice. Assessment of indirect calorimetry demonstrated restoration of metabolic flexibility in mice treated with ELA-Lys12(γGluPal), despite reductions in energy expenditure. Notably, GLP-1/apelin hybrid treatment did not affect locomotor activity, whereas liraglutide treatment was associated with marked reductions in physical activity. Histological assessment of pancreatic islets revealed that all treatment modalities induced a marked enhancement of beta cell proliferative frequency, and accompanying suppression of apoptotic rates, without major alterations in islet or beta cell areas. CONCLUSIONS/INTERPRETATION: Chronic administration of ELA, and especially ELA-Lys12(γGluPal), delivered pronounced metabolic improvements in HFF mice, with the clearest differences from liraglutide treatment evident in circulating lipids and hepatic biomarkers.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Sridhar A, Palmer ES, Craig SL, et al. Unimolecular GLP-1/APJ receptor co-agonism improves metabolism and dyslipidaemia as well as normalising hepatic triglyceride and aminotransferase elevation in high-fat-fed mice. Diabetologia. 2026. PMID: 42758304. doi:10.1007/s00125-026-06863-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。